Immunome, Inc.

Immunome's 18.21% short interest is remarkably elevated for a $2.6B biotech with no profitable earnings (P/E n/a), suggesting meaningful skepticism about its pipeline or burn rate. The stock trades near neutral RSI (48.2) and well below its 52-week high, indicating neither euphoria nor panic—yet the substantial short position creates inherent squeeze risk if clinical catalysts deliver unexpected positive data. The combination of high short exposure, pre-profitability status, and depressed valuation relative to the 52-week peak hints at a binary-outcome story where bears are heavily positioned, leaving room for violent repricing if momentum shifts.